The global humanized mouse model market size is projected to be worth US$ 101.5 million in 2023. The humanized mouse model market forecasts growth from 2023 to 2033 of 5.8% CAGR to reach US$ 178.3 million.
One of the main drivers of increased research activities in humanized mouse models is the rising demand from the healthcare sector for more thorough screening of novel drug candidates discovered to treat various chronic diseases such as cardiovascular conditions, diabetes, and cancers. From 2017 to 2022, the global humanized mouse and rat model market experienced a CAGR of 5.3%.
Key Market Highlights
Attributes | Details |
---|---|
Humanized Mouse Model Market Value for 2023 | US$ 101.5 million |
Humanized Mouse Model Market Value for 2033 | US$ 178.3 million |
Humanized Mouse Model Market CAGR from 2023 to 2033 | 5.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The humanized mouse model demand increased steadily between 2017 and 2022, accelerated by increased research into infectious illnesses, cancer, and immunology. These models were frequently utilized by academic institutions and pharmaceutical corporations for preclinical research, creating a stable humanized mouse model market.
Historical CAGR | 5.3% |
---|---|
Forecast CAGR | 5.8% |
The humanized mouse and rat model market is expected to strengthen significantly between 2023 and 2033. The introduction of customized medicine, increased investment in drug research, and an increasing focus on precision medicines are just a few of the factors that have contributed to this surge. The adoption is fueled by the need for trustworthy preclinical models replicating human physiology.
The humanized mice model market is anticipated to have significant expansion, which reflects the dynamic environment of biomedical research and medication development. Several genes have been discovered in humans but have not been discovered in their orthologous mouse counterparts.
These genetically humanized mice can offer more trustworthy in vivo information regarding human gene function in healthy physiology and disease. As a result, creating genetically modified mice that express an orthologous human gene is becoming increasingly popular.
DRIVERS
RESTRAINTS
OPPORTUNITY
CHALLENGES
Individual biomarkers are used to customize therapies in precision medicine, also known as personalized medicine. Researchers used mice to generate a PDX model for cancer by injecting immune-compromised mice with patient tumor components. Every mouse undergoes a different course of treatment, shaping patients' distinctive tumor-reduction plans.
The demand for individualized medication is set to rise with the adoption of humanized mouse models. Acute myeloid leukemia (AML) and bladder, breast, lung, pancreatic, and ovarian malignancies are just a handful of the illnesses for which Jackson Laboratory has developed more than 450 different PDX oncology mice models.
As a result of advancements in scientific research, associated tools, and technologies, customized medicine has advanced more quickly. These factors are anticipated to fuel humanized mouse model market expansion during the upcoming years.
Humanized mouse models play an integral part in discovering new drugs by providing a crucial link between laboratory research and clinical trials. These models closely resemble how people react to medications because they have immune systems and genetic makeup similar to humans. This allows researchers to evaluate the safety and efficacy of new treatments during the preclinical stages with more accuracy.
This accuracy lowers the possibility of negative outcomes in subsequent clinical studies, saving time and dollars for pharmaceutical companies. The humanized mouse model market stands to gain greatly due to the continued need for better preclinical models to advance drug development pipelines. These models are crucial in the ongoing search for safer and more potent medications.
Researchers are searching for alternatives to conventional models for human study due to increasing humanized mouse model demand from animal rights organizations to discontinue using animals for experimentation. The use of animals for testing has drawbacks, such as the demand for specialized personnel, protracted protocols, and expensive expenses. The study of diabetes uses various methods and non-traditional species, such as rapid computer simulations, artificial blood vessel testing systems, and cell culture techniques for medication investigation.
In vitro testing techniques, online patient drug registries, simulating virtual drug trials, non-invasive imaging techniques including magnetic resonance imaging (MRI) and computed tomography (CT) scans, micro-dosing, and other options are some newer possibilities.
The development of these techniques can affect how humanized mouse models are used as researchers attempt to reduce the price of drug testing. Non-animal-tested products may rise due to marketing that positions them as environmentally beneficial. These factors are anticipated to restrain the humanized mouse model market expansion throughout the forecasted period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
It is anticipated that the genetic humanized mouse models segment is going to dominate the market. This dominance is primarily related to the extensive use of genetically humanized mouse models in various experimental investigations, notably when evaluating the efficacy and safety of substances. The growing use of these mouse models to study medication metabolism and disposition boosts the humanized mouse model market revenue growth.
Leading Segment | Segment Share |
---|---|
Genetic Humanized Mice Model | 53.3% |
The significance of the genetically humanized mouse model segment is attributed to its critical contribution to accelerating drug discovery and development. Genetic humanized mouse models continue to be actively utilized by pharmaceutical and biotechnology businesses and research organizations, solidifying their position as the industry's significant source of revenue for experimental analysis and drug development.
Leading the humanized mouse model market expansion is the oncology section, which takes the lead. To understand the biology of cancer, create new treatments, and assess the effectiveness of medications, oncology research mainly relies on humanized mouse models. These models enable more precise and trustworthy preclinical research by simulating the human tumor microenvironment.
Leading Segment | Segment Share |
---|---|
Oncology | 33.2% |
Due to a pressing demand for cutting-edge cancer research and treatment development, the oncology section takes the lead. The demand for humanized mouse models in this research is anticipated to be strong as long as cancer remains a problem for the world's health, promoting advancement and innovation in cancer therapies.
Academic and Research Institutions are the main humanized mouse model demand generators. These organizations are at the bleeding edge of cutting-edge scientific research. They are actively involved in the investigation of numerous diseases, the creation of new medications, and the testing of new therapeutics. The evaluation of innovative treatments and the comprehension of disease mechanisms are made possible using humanized mouse models in preclinical investigations by academic and research institutes.
Leading Segment | Segment Share |
---|---|
Academic & Research Institutes | 43.9% |
Companies in the pharmaceutical and biotechnology industries and contract research organizations considerably contribute to the rat and mouse model market expansion. These organizations use humanized mouse models to speed up drug discovery and development, resulting in faster market entry of safer and more potent pharmaceuticals. The humanized mouse model market’s variety of end-user categories underscores the crucial role that humanized mouse models have played in improving both therapeutic innovation and medical research.
The humanized mouse model market in North America is anticipated to expand significantly. The demand for customized medicine contributes to the trend, and medication development requires using humanized mouse models for preclinical research. Improvements in genetic engineering and genome editing methods have facilitated the creation of humanized mice models that are more precise and pertinent.
Attributes | Details |
---|---|
North America Market Share | 41.4% |
United States Market Share | 32.6% |
In North America, pharmaceutical firms and academic institutions increasingly use these models to examine human diseases and evaluate potential treatments. The region's strong healthcare system and significant financial commitments to biomedical research play a role in the rat and mouse model market in North America's promising future.
Due to its critical contribution to advancing biomedical research and drug discovery, the European rat and mouse model market has a positive outlook. The adoption of humanized mouse models is being boosted by this region's dedication to cutting-edge research and healthcare innovation, allowing for more precise disease modeling and preclinical testing. Developments in gene editing technologies have significantly enhanced the accuracy and applicability of these models.
Attributes | Details |
---|---|
Europe Market Share | 33.4% |
Germany Market Share | 7.9% |
United Kingdom Market CAGR | 5.9% |
Humanized mouse models are used more frequently by European pharmaceutical corporations and academic institutions to study diseases, assess prospective treatments, and create customized medicine methods. The European humanized mouse model market benefits from a strong healthcare infrastructure and significant investments in the life sciences industry, strengthening its position as a center for creating humanized mouse models.
The Asia Pacific humanized mouse model market is expected to grow rapidly in the future years. The region's booming pharmaceutical and biotechnology companies and a growing emphasis on precision medicine are propelling the use of humanized mouse models for preclinical research. Advances in genetic engineering and genome editing techniques have created more sophisticated and relevant models, increasing their utility in disease modeling and medication testing.
Attributes | Details |
---|---|
India Market CAGR | 5.8% |
China Market CAGR | 7.0% |
Japan Market Share | 4.1% |
In Asia Pacific, academic institutions, research organizations, and pharmaceutical corporations progressively incorporate these models into their research workflows. The Asia Pacific is emerging as a leading global humanized mouse model market player. It has substantial potential for innovation and scientific development due to a growing healthcare infrastructure and increased investments in life sciences.
Due to the rising need for preclinical research tools in immunology and drug development, the humanized mouse model industry has a dynamic and varied competitive environment. These businesses use genetic modification methods like CRISPR/Cas9 to create customized mouse models and provide a wide range of humanized mouse models and related services.
Collaborations with pharmaceutical and biotechnology companies for illness modeling and medication testing accelerate competition. Emerging humanized mouse model manufacturers break into the industry, encouraging innovation and healthy competition.
Recent Paradigm Shifts
Company | Taconic Biosciences |
---|---|
Details | The huNOG-EXL EA humanized immune system (HIS) mouse was introduced in January 2022 by Taconic Biosciences, a leader in providing drug research animal model solutions. Taconic's widely utilized HIS portfolio is widened with this offering. The study window in which a myeloid-lineage HIS mouse model can be successfully used is greatly extended by huNOG-EXL EA. |
Company | genOway |
---|---|
Details | Axenis, a firm committed to the creation of immunocompromised models for the validation of novel and innovative therapies, was acquired by genOway, a biotechnology company focused on the design and development of preclinical models, in September 2021. |
Company | The Jackson Laboratory |
---|---|
Details | The Jackson Laboratory (JAX), a nonprofit biomedical research organization, announced in October 2021 that it has acquired the Research Models & Services (RMS) division of Charles River Laboratories Japan as a wholly owned subsidiary. The Jackson Laboratory Japan, a company based in Japan, has about 250 workers, three production facilities in Atsugi, Hino, and Tsukuba, as well as an administrative office in Yokohama. |
Prominent Humanized Mouse Model Manufacturers
The humanized mouse model market to secure a valuation of US$ 101.5 million in 2023.
The humanized mouse model market is estimated to reach US$ 178.3 million by 2033.
Through 2033, the market is anticipated to expand at a 5.8% CAGR.
From 2017 to 2022, the market recorded a 5.3% HCAGR.
The genetic humanized mice model sector is set to achieve a market share of 53.3%.
A 43.9% mice model market share is expected for the academic & research institutes sector.
The China humanized mouse and rat model market to exhibit a CAGR of 7.0% through 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Model Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Model Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Model Type, 2023 to 2033 5.3.1. Genetic 5.3.2. Cell-based 5.3.2.1. CD34 5.3.2.2. PBMC 5.3.2.3. BLT 5.4. Y-o-Y Growth Trend Analysis By Model Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Model Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Oncology 6.3.2. Immunology and Infectious Diseases 6.3.3. Neuroscience 6.3.4. Toxicology 6.3.5. Hematopoiesis 6.3.6. Others 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Pharmaceutical & Biotechnology Companies 7.3.2. Contract Research Organizations 7.3.3. Academic & Research Institutions 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Model Type 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Model Type 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Model Type 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Model Type 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. U.K. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Model Type 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Model Type 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Model Type 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Model Type 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Model Type 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Model Type 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Model Type 14.2.3. By Application 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Model Type 14.3.3. By Application 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Model Type 15.2.3. By Application 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Model Type 15.3.3. By Application 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.S. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Model Type 16.1.2.2. By Application 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Model Type 16.2.2.2. By Application 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Model Type 16.3.2.2. By Application 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Model Type 16.4.2.2. By Application 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Model Type 16.5.2.2. By Application 16.5.2.3. By End User 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Model Type 16.6.2.2. By Application 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Model Type 16.7.2.2. By Application 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Model Type 16.8.2.2. By Application 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Model Type 16.9.2.2. By Application 16.9.2.3. By End User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Model Type 16.10.2.2. By Application 16.10.2.3. By End User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Model Type 16.11.2.2. By Application 16.11.2.3. By End User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Model Type 16.12.2.2. By Application 16.12.2.3. By End User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Model Type 16.13.2.2. By Application 16.13.2.3. By End User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Model Type 16.14.2.2. By Application 16.14.2.3. By End User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Model Type 16.15.2.2. By Application 16.15.2.3. By End User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Model Type 16.16.2.2. By Application 16.16.2.3. By End User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Model Type 16.17.2.2. By Application 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Model Type 16.18.2.2. By Application 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Model Type 16.19.2.2. By Application 16.19.2.3. By End User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Model Type 16.20.2.2. By Application 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Model Type 16.21.2.2. By Application 16.21.2.3. By End User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Model Type 16.22.2.2. By Application 16.22.2.3. By End User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Model Type 16.23.2.2. By Application 16.23.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Model Type 17.3.3. By Application 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Ingenious Targeting Laboratory 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Axenis S.A.S 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Trans Genic Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Horizon Discovery Group PLC 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. HuMurine Technologies 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Champions Oncology Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Genoway S.A. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Crown Bioscience Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Taconic Biosciences Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. The Jackson Laboratory 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 18.1.11. Vitalstar Biotechnology Co. Ltd. 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.11.5.2. Product Strategy 18.1.11.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports